Skip to Content

Generic Evamist Availability

Evamist is a brand name of estradiol, approved by the FDA in the following formulation(s):

EVAMIST (estradiol - spray;transdermal)

  • Manufacturer: ELAN PHARMA INTL LTD
    Approval date: July 27, 2007
    Strength(s): 1.53MG/SPRAY [RLD]

Has a generic version of Evamist been approved?

No. There is currently no therapeutically equivalent version of Evamist available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evamist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Dermal penetration enhancers and drug delivery systems involving same
    Patent 6,299,900
    Issued: October 9, 2001
    Inventor(s): Reed; Barry Leonard & Morgan; Timothy Matthias & Finnin; Barrie Charles
    Assignee(s): Monash University
    A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
    Patent expiration dates:
    • February 19, 2017
      ✓ 
      Patent use: MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE)
      ✓ 
      Drug product
    • February 19, 2017
      ✓ 
      Patent use: FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
      ✓ 
      Drug product
  • Dermal penetration enhancers and drug delivery systems involving same
    Patent 6,818,226
    Issued: November 16, 2004
    Inventor(s): Barry Leonard; Reed & Timothy Matthias; Morgan & Barrie Charles; Finnin
    Assignee(s): ACRUX DDS Pty. Ltd.
    A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
    Patent expiration dates:
    • February 19, 2017
      ✓ 
      Patent use: MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE)
      ✓ 
      Drug product
    • February 19, 2017
      ✓ 
      Patent use: FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
      ✓ 
      Drug product
  • Transdermal delivery of hormones
    Patent 6,923,983
    Issued: August 2, 2005
    Inventor(s): Morgan; Timothy Matthias & Bakalova; Margarita Vladislavova & Klose; Karthryn Traci-Jane & Finnin; Barrie Charles & Reed; Barry Leonard
    Assignee(s): Acrux DDS PTY LTD
    The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone to an animal which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention
    Patent expiration dates:
    • February 19, 2017
      ✓ 
      Patent use: MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE)
      ✓ 
      Drug product
    • February 19, 2017
      ✓ 
      Patent use: FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
      ✓ 
      Drug product
  • Dispensing device
    Patent 6,978,945
    Issued: December 27, 2005
    Inventor(s): Wong; Kon Euan & Bayly; Mark Simon
    Assignee(s): Acrux DDS Pty Ltd
    Hand-held dispensing devices for dispensing and applying a substance to the skin of a host are described. The devices include a hollow body, a capsule mounted within the hollow body for containing the substance, a nozzle mounted within the hollow body communicating with the substance in the capsule, an actuator to cause metered quantities of the substance to be dispensed from the capsule through the nozzle, a shroud defining an exit space for receiving the substance emerging from the nozzle, and a cap detachably mounted on the shroud to selectively open and close the nozzle and thereby control escape of the substance from the capsule.
    Patent expiration dates:
    • July 31, 2022
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide